SCHEMBL3337508

SCHEMBL3337508

COc1cccc(-c2csc(NNC(=O)c3cccs3)n2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 1.00
KDM4E B2RXH2 6/20 1.00
POLB P06746 2/20 1.00
MAPK1 P28482 2/20 0.70
GAA P10253 2/20 0.70
RAB9A P51151 7/20 0.62
NPC1 O15118 6/20 0.62
ALDH1A1 P00352 6/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
HTT P42858 2/20 0.62
HSD17B10 Q99714 2/20 0.62
HPGD P15428 2/20 0.62
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
CSNK2A1 P68400 1/20 0.56
THRB P10828 1/20 0.54
TP53 P04637 1/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
LMNA P02545 5/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341553 0.85 MAPT (0.74) MAPTKDM4EPOLBMAPK1GAA
SCHEMBL3335896 0.83 MAPT (1.00) MAPTKDM4EPOLBMAPK1GAA
SCHEMBL3340858 0.82 MAPT (0.70) MAPTKDM4EPOLBMAPK1GAA
SCHEMBL10923238 0.78 ALDH1A1 (0.83) MAPTKDM4EPOLBRAB9ANPC1
SCHEMBL10809915 0.78 MEN1 (0.86) MAPTKDM4EPOLBRAB9ANPC1
SCHEMBL12296213 0.77 RAB9A (0.76) MAPTKDM4EPOLBMAPK1RAB9A
SCHEMBL2754062 0.77 MAPT (0.83) MAPTKDM4EPOLBMAPK1RAB9A
SCHEMBL2753867 0.76 ADORA3 (0.80) MAPTKDM4EPOLBMAPK1RAB9A
SCHEMBL1822075 0.76 ALDH1A1 (0.77) MAPTKDM4EGAARAB9ANPC1
SCHEMBL11137552 0.75 ALDH1A1 (0.78) MAPTKDM4EPOLBGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885KDM4E 4489/4885POLB 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.